"They can be small or grow large and create symptoms you won't see for some time." At least two Pensacola law firms have now ...

Twenty-eight years after the incident, survivors lament how their lives have been negatively altered, writes VICTOR AYENI In ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Revenue in 2025 will be $61 billion to $64 billion, Pfizer said, in line with predictions by Wall Street analysts.